{"organizations": [], "uuid": "b7bb08d0c7ce652ad60bc48f47baee8925da37f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-magenta-therapeutics-and-heidelber/brief-magenta-therapeutics-and-heidelberg-pharma-sign-agreement-for-development-of-antibody-drug-conjugates-idUSFWN1QN0FT", "country": "US", "domain_rank": 408, "title": "BRIEF-Magenta Therapeutics And Heidelberg Pharma Sign Agreement For Development Of Antibody Drug Conjugates", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.28, "site_type": "news", "published": "2018-03-05T22:36:00.000+02:00", "replies_count": 0, "uuid": "b7bb08d0c7ce652ad60bc48f47baee8925da37f9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-magenta-therapeutics-and-heidelber/brief-magenta-therapeutics-and-heidelberg-pharma-sign-agreement-for-development-of-antibody-drug-conjugates-idUSFWN1QN0FT", "ord_in_thread": 0, "title": "BRIEF-Magenta Therapeutics And Heidelberg Pharma Sign Agreement For Development Of Antibody Drug Conjugates", "locations": [], "entities": {"persons": [], "locations": [{"name": "heidelberg", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "heidelberg pharma ag", "sentiment": "negative"}, {"name": "pharma", "sentiment": "negative"}, {"name": "pharma ag - ‍magenta", "sentiment": "none"}, {"name": "heidelberg pharma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "pharma ag", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Heidelberg Pharma Ag:\n* MAGENTA THERAPEUTICS AND HEIDELBERG PHARMA SIGN EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES\n* HEIDELBERG PHARMA AG - ‍MAGENTA WILL HAVE ACCESS TO CO’S AMANITIN TOXIN-LINKER PLATFORM TECHNOLOGY​\n* HEIDELBERG PHARMA AG -MAGENTA HAS OPTION FOR EXCLUSIVE TARGET-SPECIFIC LICENSE FOR GLOBAL DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT CANDIDATES\n* HEIDELBERG PHARMA AG - ‍CO TO RECEIVE UPFRONT TECHNOLOGY ACCESS, EXCLUSIVITY FEES, PAYMENTS FOR RESEARCH SUPPORT​\n* HEIDELBERG PHARMA - TO BE ELIGIBLE TO RECEIVE OPTION FEES, DEVELOPMENT, REGULATORY,SALES-RELATED MILESTONE PAYMENTS UP TO $334 MILLION, UNDER CONDITIONS​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T22:36:00.000+02:00", "crawled": "2018-03-06T22:37:38.035+02:00", "highlightTitle": ""}